How GLP-1 meds affect resistance training in adults with obesity/diabetes
Official title: Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Run by Ohio State University · NCT07702461 · Data updated 2026-11-12
This study tests whether adults taking a GLP-1 receptor agonist can better preserve or gain muscle when they do resistance training.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Ohio State University Academic / other |
| Locations | 1 site (Columbus, Ohio) |
| Status | Recruiting |
| Started | June 12, 2026 |
| Main results expected | October 2026 |
| Study ends | January 2027 |
| Registry record updated | July 24, 2026 |
| Trial ID | NCT07702461 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years or older currently using a GLP-1 receptor agonist for 3 months or longer, with the ability to respond to English surveys.
✕Probably not a fit
Individuals not engaging in or unable to perform resistance training or who do not follow GLP-1 therapy as prescribed may see limited applicability.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study follows adults on a GLP-1 receptor agonist (such as semaglutide or liraglutide) to see how their resistance-training habits relate to changes in lean muscle over time. Participants are adults 18+ who have been on GLP-1 medications for at least 3 months and complete surveys about their training and daily function. Data will help understand how resistance training interacts with GLP-1 therapy and body composition in real-world settings.
Why it matters
Potential benefit: If successful, the findings could guide personalized recommendations for combining GLP-1 therapy with resistance training to protect muscle mass.
How similar studies have gone: Prior work supports the idea that resistance training preserves muscle during weight loss, but studies specifically in GLP-1–treated populations are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult aged 18 years or older * Currently taking a GLP-1 receptor agonist medication * On the GLP-1 receptor agonist for at least 3 months * Using the GLP-1 receptor agonist for type 2 diabetes, overweight or obesity, and/or weight management (self-reported) * Stable GLP-1 receptor agonist dose for the past 4 to 8 weeks * Able to read and respond to the survey in English * Willing and able to provide informed consent electronically Exclusion Criteria: * Currently or planning to become pregnant * Planned bariatric surgery within the next 3 months * Recent bariatric surgery (within the past 3 months) or other conditions that substantially alter resistance training capacity (e.g., advanced cancer cachexia, severe mobility-limiting conditions) * Unable to read or respond to the survey in English
Where it's running
-
The Ohio State University
Columbus, Ohio, United States Recruiting
Study contacts
- Study coordinator: Madison L Kackley, PhD
- Email: kackley.19@osu.edu
- Phone: 614-247-9650
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
NTU JO-SMART Program for Obesity and Knee Osteoarthritis
A program that combines AI-guided community exercise with continuous glucose monitoring to help people who are overweight and have knee OA see if it improves blood sugar and joint health.
-
How incretin treatments affect muscle mass and function in people with overweight or obesity
This study will see how drugs like semaglutide and tirzepatide influence fat-free mass, muscle strength, and physical function in adults with overweight or obesity.
-
Dose find for remimazolam plus alfentanil for gastroscopy in obese adults
This trial tests what dose of remimazolam besylate with alfentanil best sedates obese adults during gastroscopy.
-
Continuous temperature monitoring of the feet with connected insoles and a smartphone app in adults with diabetes at high risk
This trial tests whether the Solsius SelfCare system can reliably flag pre-ulcer foot changes in adults with diabetes by detecting temperature differences between feet for at least two consecutive days.
-
Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults
This study compares how much weight adults lose over two years when starting GLP-1 medicines versus adults who had sleeve gastrectomy at the same center.
-
Gut barrier and inflammation after fast-food overfeeding in adults
This study tests whether 14 days of fast-food overfeeding can alter gut barrier function and trigger inflammation in adults who are generally healthy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.